Hostname: page-component-586b7cd67f-2plfb Total loading time: 0 Render date: 2024-11-25T22:36:21.785Z Has data issue: false hasContentIssue false
  • English
  • Français

Efficacy of paliperidone palmitate 3-month formulation in preventing hospital admissions. 60 months of follow-up

Published online by Cambridge University Press:  01 September 2022

S.L. Romero Guillena ,
B.O. Plasencia Garcia De Diego  and
F. Gotor Sanchez-Luengo
S.L. Romero Guillena*
Affiliation:
UGC Salud Mental Virgen Macarena,, Psychiatry, seville, Spain
B.O. Plasencia Garcia De Diego
Affiliation:
Virgen del Rocio Hospital, Psychiatry, Seville, Spain
F. Gotor Sanchez-Luengo
Affiliation:
Virgen del Rocio Hospital, Psychiatry, Seville, Spain
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Paliperidone Palmitate 3-month formulation (PP3M) has shown a significantly longer time to relapse compared to placebo, with similar efficacy and safety to Paliperidone Palmitate 1-month (PP1M). However, studies of longer duration are required.

Objectives

The main objective of this study is to determine the effectiveness of PP3M in the prevention of hospitalizations in patients with non-acute schizophrenia in a naturalistic outpatient psychiatric setting.

Methods

Sample: 30 patients diagnosed with schizophrenia (DSM 5) that started treatment with PP3M after being stabilized with PP1M (the treatment dose was not changed in the four months before study inclusion) The mean dose of PP3M was 401. 55 mg Quarterly basis, the following evaluations were performed during a follow-up period of 60 months: The Clinical Global Impression-Schizophrenia scale (CGI-SCH) Treatment adherence, concomitant medication, and the number of hospitalizations. Efficacy values: Percentage of patients who remained free of admissions at the end of 60 months of follow-up. Other evaluation criteria: Average change from baseline visit to the final evaluation as assessed by score obtained on the following scale: GSI-SCH; percentage of patients on antipsychotic monotherapy, and treatment adherence rate.

Results

The percentage of patients who remained free of admissions at the end of the 60 months was 83.25%. Mean variations from baseline scores at 60 months were: (-0.36 ±0-37) on the GCI-SCH. The rate of adherence to treatment with PP3M after 60 months was 86.58%.

Conclusions

In our study, we found that paliperidone palmitate 3-month formulation effectively prevents admissions under daily clinical practice conditions.

Disclosure

No significant relationships.

Keywords

hospital admissionsPaliperidone Palmitate 3-month formulationschizophréniaEfficacy
Type
Abstract
Information
European Psychiatry , Volume 65 , Special Issue S1: Abstracts of the 30th European Congress of Psychiatry , June 2022 , pp. S285 - S286
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.